{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T21:24:44Z","timestamp":1790717084335,"version":"4.1.0"},"reference-count":145,"publisher":"MDPI AG","issue":"1","license":[{"start":{"date-parts":[[2021,12,30]],"date-time":"2021-12-30T00:00:00Z","timestamp":1640822400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Science Foundation of China","doi-asserted-by":"publisher","award":["81803464"],"award-info":[{"award-number":["81803464"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Natural Science Foundations of Shandong Province","award":["ZR2018BH041"],"award-info":[{"award-number":["ZR2018BH041"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biomolecules"],"abstract":"<jats:p>Bortezomib (BTZ) is the first proteasome inhibitor approved by the Food and Drug Administration. It can bind to the amino acid residues of the 26S proteasome, thereby causing the death of tumor cells. BTZ plays an irreplaceable role in the treatment of mantle cell lymphoma and multiple myeloma. Moreover, its use in the treatment of other hematological cancers and solid tumors has been investigated in numerous clinical trials and preclinical studies. Nevertheless, the applications of BTZ are limited due to its insufficient specificity, poor permeability, and low bioavailability. Therefore, in recent years, different BTZ-based drug delivery systems have been evaluated. In this review, we firstly discussed the functions of proteasome inhibitors and their mechanisms of action. Secondly, the properties of BTZ, as well as recent advances in both clinical and preclinical research, were reviewed. Finally, progress in research regarding BTZ-based nanoformulations was summarized.<\/jats:p>","DOI":"10.3390\/biom12010051","type":"journal-article","created":{"date-parts":[[2021,12,30]],"date-time":"2021-12-30T21:41:21Z","timestamp":1640900481000},"page":"51","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":52,"title":["Progress on the Application of Bortezomib and Bortezomib-Based Nanoformulations"],"prefix":"10.3390","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5755-7318","authenticated-orcid":false,"given":"Jianhao","family":"Liu","sequence":"first","affiliation":[{"name":"School of Pharmacy, Weifang Medical University, Weifang 261053, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1945-012X","authenticated-orcid":false,"given":"Ruogang","family":"Zhao","sequence":"additional","affiliation":[{"name":"School of Pharmacy, Weifang Medical University, Weifang 261053, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaowen","family":"Jiang","sequence":"additional","affiliation":[{"name":"School of Pharmacy, Weifang Medical University, Weifang 261053, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhaohuan","family":"Li","sequence":"additional","affiliation":[{"name":"School of Pharmacy, Weifang Medical University, Weifang 261053, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo","family":"Zhang","sequence":"additional","affiliation":[{"name":"School of Pharmacy, Weifang Medical University, Weifang 261053, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2021,12,30]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1080\/07853890410030877","article-title":"Proteasome inhibition in hematologic malignancies","volume":"36","author":"Richardson","year":"2004","journal-title":"Ann. Med."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"T1","DOI":"10.1530\/ERC-14-0005","article-title":"The ubiquitin-proteasome system: Opportunities for therapeutic intervention in solid tumors","volume":"22","author":"Johnson","year":"2015","journal-title":"Endocr. Relat. Cancer"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"2034","DOI":"10.1158\/1535-7163.MCT-11-0433","article-title":"Mechanism of action of proteasome inhibitors and deacetylase inhibitors and the biological basis of synergy in multiple myeloma","volume":"10","author":"Hideshima","year":"2011","journal-title":"Mol. Cancer Ther."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/S0960-894X(98)00029-8","article-title":"Potent and selective inhibitors of the proteasome: Dipeptidyl boronic acids","volume":"8","author":"Adams","year":"1998","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/j.cbi.2010.12.026","article-title":"Proteasome inhibitors MG-132 and bortezomib induce AKR1C1, AKR1C3, AKR1B1, and AKR1B10 in human colon cancer cell lines SW-480 and HT-29","volume":"191","author":"Ebert","year":"2011","journal-title":"Chem. Biol. Interact."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/S1535-6108(02)00127-7","article-title":"Distinct BH3 domains either sensitize or activate mitochondrial apoptosis, serving as prototype cancer therapeutics","volume":"2","author":"Letai","year":"2002","journal-title":"Cancer Cell"},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Yang, M.H., Jung, S.H., Chinnathambi, A., Alahmadi, T.A., Alharbi, S.A., Sethi, G., and Ahn, K.S. (2019). Attenuation of STAT3 Signaling Cascade by Daidzin Can Enhance the Apoptotic Potential of Bortezomib against Multiple Myeloma. Biomolecules, 10.","DOI":"10.3390\/biom10010023"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1654","DOI":"10.1182\/blood-2007-08-105601","article-title":"Combination of proteasome inhibitors bortezomib and NPI-0052 trigger in vivo synergistic cytotoxicity in multiple myeloma","volume":"111","author":"Chauhan","year":"2008","journal-title":"Blood"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1200\/JCO.2005.03.108","article-title":"Phase II study of proteasome inhibitor bortezomib in relapsed or refractory B-cell non-Hodgkin\u2019s lymphoma","volume":"23","author":"Goy","year":"2005","journal-title":"J. Clin. Oncol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"5036","DOI":"10.1158\/0008-5472.CAN-03-2707","article-title":"Bortezomib as a potential treatment for prostate cancer","volume":"64","author":"Papandreou","year":"2004","journal-title":"Cancer Res."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1016\/j.lungcan.2009.07.011","article-title":"A randomized phase II study of bortezomib and pemetrexed, in combination or alone, in patients with previously treated advanced non-small-cell lung cancer","volume":"68","author":"Scagliotti","year":"2010","journal-title":"Lung Cancer"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1177\/1078155210386268","article-title":"Stability of unused reconstituted bortezomib in original manufacturer vials","volume":"17","author":"Vanderloo","year":"2011","journal-title":"J. Oncol. Pharm. Pract."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"589","DOI":"10.2217\/nnm.10.27","article-title":"Galactosylated nanocrystallites of insoluble anticancer drug for liver-targeting therapy: An in vitro evaluation","volume":"5","author":"Wei","year":"2010","journal-title":"Nanomedicine"},{"key":"ref_14","first-page":"102","article-title":"Sensitizing human multiple myeloma cells to the proteasome inhibitor bortezomib by novel curcumin analogs","volume":"29","author":"Mujtaba","year":"2012","journal-title":"Int. J. Mol. Med."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1016\/S1470-2045(20)30525-8","article-title":"Venetoclax or placebo in combination with bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma (BELLINI): A randomised, double-blind, multicentre, phase 3 trial","volume":"21","author":"Kumar","year":"2020","journal-title":"Lancet Oncol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1186\/s12951-020-00612-7","article-title":"Preparation, characterization and in vitro-in vivo evaluation of bortezomib supermolecular aggregation nanovehicles","volume":"18","author":"Chen","year":"2020","journal-title":"J. Nanobiotechnology"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"4254","DOI":"10.1039\/C9CC01344J","article-title":"Folate-targeted pH-sensitive bortezomib conjugates for cancer treatment","volume":"55","author":"Liu","year":"2019","journal-title":"Chem. Commun."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"6969","DOI":"10.2147\/CMAR.S255682","article-title":"Inhibition of Multiple Myeloma Using 5-Aza-2\u2032-Deoxycytidine and Bortezomib-Loaded Self-Assembling Nanoparticles","volume":"12","author":"Che","year":"2020","journal-title":"Cancer Manag. Res."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1080\/03639045.2018.1483385","article-title":"Bortezomib-loaded solid lipid nanoparticles: Preparation, characterization, and intestinal permeability investigation","volume":"44","author":"Mahmoudian","year":"2018","journal-title":"Drug Dev. Ind. Pharm."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1016\/S2215-0366(19)30520-6","article-title":"The ubiquitin proteasome system and schizophrenia","volume":"7","author":"Luza","year":"2020","journal-title":"Lancet Psychiatry"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1146\/annurev-biochem-061516-044859","article-title":"The Ubiquitin System, Autophagy, and Regulated Protein Degradation","volume":"86","author":"Varshavsky","year":"2017","journal-title":"Annu. Rev. Biochem."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.semcancer.2015.09.014","article-title":"Small molecule therapeutics targeting F-box proteins in cancer","volume":"36","author":"Liu","year":"2016","journal-title":"Semin. Cancer Biol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1016\/j.cell.2017.04.023","article-title":"The Logic of the 26S Proteasome","volume":"169","author":"Collins","year":"2017","journal-title":"Cell"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1126\/science.aax3769","article-title":"Cellular quality control by the ubiquitin-proteasome system and autophagy","volume":"366","author":"Pohl","year":"2019","journal-title":"Science"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"100858","DOI":"10.1016\/j.preteyeres.2020.100858","article-title":"Mechanisms of mitochondrial dysfunction and their impact on age-related macular degeneration","volume":"79","author":"Kaarniranta","year":"2020","journal-title":"Prog. Retin. Eye Res."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.jconrel.2015.05.286","article-title":"Tumor vascular targeted liposomal-bortezomib minimizes side effects and increases therapeutic activity in human neuroblastoma","volume":"211","author":"Zuccari","year":"2015","journal-title":"J. Control Release"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"100663","DOI":"10.1016\/j.drup.2019.100663","article-title":"Targeting the ubiquitin-proteasome pathway to overcome anti-cancer drug resistance","volume":"48","author":"Narayanan","year":"2020","journal-title":"Drug Resist. Updates"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"e925","DOI":"10.1038\/cddis.2013.440","article-title":"Bortezomib antagonizes microtubule-interfering drug-induced apoptosis by inhibiting G2\/M transition and MCL-1 degradation","volume":"4","author":"Rapino","year":"2013","journal-title":"Cell Death Dis."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1038\/s41419-019-1881-x","article-title":"Parkin facilitates proteasome inhibitor-induced apoptosis via suppression of NF-\u03baB activity in hepatocellular carcinoma","volume":"10","author":"Zhang","year":"2019","journal-title":"Cell Death Dis."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"7244","DOI":"10.1002\/cam4.3347","article-title":"ZHX2 mediates proteasome inhibitor resistance via regulating nuclear translocation of NF-\u03baB in multiple myeloma","volume":"9","author":"Jiang","year":"2020","journal-title":"Cancer Med."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1182\/blood-2006-03-013128","article-title":"NPI-0052, a novel proteasome inhibitor, induces caspase-8 and ROS-dependent apoptosis alone and in combination with HDAC inhibitors in leukemia cells","volume":"110","author":"Miller","year":"2007","journal-title":"Blood"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.lfs.2014.08.024","article-title":"Melatonin as a proteasome inhibitor. Is there any clinical evidence?","volume":"115","author":"Vriend","year":"2014","journal-title":"Life Sci."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1038\/s41419-020-02910-2","article-title":"The BCL-2 selective inhibitor ABT-199 sensitizes soft tissue sarcomas to proteasome inhibition by a concerted mechanism requiring BAX and NOXA","volume":"11","author":"Muenchow","year":"2020","journal-title":"Cell Death Dis."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"3458","DOI":"10.1038\/s41388-019-0675-z","article-title":"Proteasome inhibition boosts autophagic degradation of ubiquitinated-AGR2 and enhances the antitumor efficiency of bevacizumab","volume":"38","author":"Wang","year":"2019","journal-title":"Oncogene"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1707","DOI":"10.3109\/10428194.2013.828351","article-title":"The proteasome: Mechanisms of biology and markers of activity and response to treatment in multiple myeloma","volume":"55","author":"Manasanch","year":"2014","journal-title":"Leuk. Lymphoma"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"27864","DOI":"10.1074\/jbc.M201519200","article-title":"Evidence that inhibition of p44\/42 mitogen-activated protein kinase signaling is a factor in proteasome inhibitor-mediated apoptosis","volume":"277","author":"Orlowski","year":"2002","journal-title":"J. Biol. Chem."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/j.jmb.2009.09.038","article-title":"The 20S proteasome as an assembly platform for the 19S regulatory complex","volume":"394","author":"Hendil","year":"2009","journal-title":"J. Mol. Biol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2165\/00126839-200708010-00001","article-title":"Proteasome inhibitors in the clinical setting: Benefits and strategies to overcome multiple myeloma resistance to proteasome inhibitors","volume":"8","author":"Cheriyath","year":"2007","journal-title":"Drugs R D"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"298","DOI":"10.2174\/1574891X113089990033","article-title":"The significance of ubiquitin proteasome pathway in cancer development","volume":"8","author":"Yerlikaya","year":"2013","journal-title":"Recent Pat. Anticancer Drug Discov."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1158\/1535-7163.MCT-08-0534","article-title":"Vorinostat and bortezomib exert synergistic antiproliferative and proapoptotic effects in colon cancer cell models","volume":"8","author":"Pitts","year":"2009","journal-title":"Mol. Cancer Ther."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.biocel.2018.06.001","article-title":"Ubiquitination: Friend and foe in cancer","volume":"101","author":"Mansour","year":"2018","journal-title":"Int. J. Biochem Cell Biol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1053\/j.seminhematol.2012.04.002","article-title":"Targeting the ubiquitin+proteasome system in solid tumors","volume":"49","author":"Driscoll","year":"2012","journal-title":"Semin. Hematol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"232","DOI":"10.2174\/156802610790725515","article-title":"Proteasome inhibitors: Recent advances and new perspectives in medicinal chemistry","volume":"10","author":"Genin","year":"2010","journal-title":"Curr. Top. Med. Chem."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1586\/14737140.5.3.465","article-title":"Proteasome inhibition as a therapeutic strategy for hematologic malignancies","volume":"5","author":"Mitsiades","year":"2005","journal-title":"Expert Rev. Anticancer Ther."},{"key":"ref_45","doi-asserted-by":"crossref","unstructured":"Gelman, J.S., Sironi, J., Berezniuk, I., Dasgupta, S., Castro, L.M., Gozzo, F.C., Ferro, E.S., and Fricker, L.D. (2013). Alterations of the intracellular peptidome in response to the proteasome inhibitor bortezomib. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0053263"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"8582","DOI":"10.1074\/jbc.M509043200","article-title":"Importance of the different proteolytic sites of the proteasome and the efficacy of inhibitors varies with the protein substrate","volume":"281","author":"Kisselev","year":"2006","journal-title":"J. Biol. Chem."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1038\/nmeth759","article-title":"Activity probe for in vivo profiling of the specificity of proteasome inhibitor bortezomib","volume":"2","author":"Berkers","year":"2005","journal-title":"Nat. Methods"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1080\/10428194.2016.1214953","article-title":"Enzymatic activities of circulating plasma proteasomes in newly diagnosed multiple myeloma patients treated with carfilzomib, lenalidomide and dexamethasone","volume":"58","author":"Manasanch","year":"2017","journal-title":"Leuk. Lymphoma"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1007\/s40262-018-0702-1","article-title":"Clinical Pharmacology of Ixazomib: The First Oral Proteasome Inhibitor","volume":"58","author":"Gupta","year":"2019","journal-title":"Clin. Pharmacokinet."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1007\/s40265-016-0548-5","article-title":"Ixazomib: First Global Approval","volume":"76","author":"Shirley","year":"2016","journal-title":"Drugs"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"114255","DOI":"10.1016\/j.bcp.2020.114255","article-title":"The active second-generation proteasome inhibitor oprozomib reverts the oxaliplatin-induced neuropathy symptoms","volume":"182","author":"Caputi","year":"2020","journal-title":"Biochem. Pharmacol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"1872","DOI":"10.1080\/10428194.2016.1263842","article-title":"Phase I\/II study of the novel proteasome inhibitor delanzomib (CEP-18770) for relapsed and refractory multiple myeloma","volume":"58","author":"Vogl","year":"2017","journal-title":"Leuk. Lymphoma"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1111\/j.1365-2141.2010.08144.x","article-title":"Pharmacodynamic and efficacy studies of the novel proteasome inhibitor NPI-0052 (marizomib) in a human plasmacytoma xenograft murine model","volume":"149","author":"Singh","year":"2010","journal-title":"Br. J. Haematol."},{"key":"ref_54","first-page":"592","article-title":"Ubiquitin-proteasome pathway and prostate cancer","volume":"36","author":"Chen","year":"2013","journal-title":"Onkologie"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1007\/s12032-020-01445-y","article-title":"Proteasome inhibitors attenuates mitoxantrone-triggered immunogenic cell death in prostate cancer cells","volume":"37","author":"Wei","year":"2020","journal-title":"Med. Oncol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"5259","DOI":"10.7150\/thno.42705","article-title":"Marizomib suppresses triple-negative breast cancer via proteasome and oxidative phosphorylation inhibition","volume":"10","author":"Raninga","year":"2020","journal-title":"Theranostics"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/1475-2867-5-18","article-title":"Preclinical evaluation of the proteasome inhibitor bortezomib in cancer therapy","volume":"5","author":"Boccadoro","year":"2005","journal-title":"Cancer Cell Int."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/S1470-2045(11)70081-X","article-title":"Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: A randomised, phase 3, non-inferiority study","volume":"12","author":"Moreau","year":"2011","journal-title":"Lancet Oncol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1038\/sj.onc.1210744","article-title":"BCL-2 family regulation by the 20S proteasome inhibitor bortezomib","volume":"27","author":"Fennell","year":"2008","journal-title":"Oncogene"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1111\/j.1743-7563.2012.01535.x","article-title":"MG132, a proteasome inhibitor, induces apoptosis in tumor cells","volume":"9","author":"Guo","year":"2013","journal-title":"Asia Pac. J. Clin. Oncol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1016\/S1734-1140(13)71494-4","article-title":"Proteasome inhibitor inhibits proliferation and induces apoptosis in renal interstitial fibroblasts","volume":"65","author":"Zhu","year":"2013","journal-title":"Pharmacol. Rep."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"13052","DOI":"10.1038\/s41598-017-13533-7","article-title":"Bortezomib promotes KHSV and EBV lytic cycle by activating JNK and autophagy","volume":"7","author":"Granato","year":"2017","journal-title":"Sci. Rep."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"2108","DOI":"10.1200\/JCO.2004.02.106","article-title":"Phase I trial of the proteasome inhibitor bortezomib in patients with advanced solid tumors with observations in androgen-independent prostate cancer","volume":"22","author":"Papandreou","year":"2004","journal-title":"J. Clin. Oncol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1038\/nrd1959","article-title":"Success in translational research: Lessons from the development of bortezomib","volume":"5","year":"2006","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1158\/1541-7786.MCR-08-0108","article-title":"Bortezomib-resistant nuclear factor-kappaB activity in multiple myeloma cells","volume":"6","author":"Markovina","year":"2008","journal-title":"Mol. Cancer Res."},{"key":"ref_66","doi-asserted-by":"crossref","unstructured":"Kim, C., Lee, J.H., Ko, J.H., Chinnathambi, A., Alharbi, S.A., Shair, O.H.M., Sethi, G., and Ahn, K.S. (2019). Formononetin Regulates Multiple Oncogenic Signaling Cascades and Enhances Sensitivity to Bortezomib in a Multiple Myeloma Mouse Model. Biomolecules, 9.","DOI":"10.3390\/biom9070262"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"4706","DOI":"10.1167\/iovs.06-1147","article-title":"The proteasome inhibitor bortezomib induces apoptosis in human retinoblastoma cell lines in vitro","volume":"48","author":"Poulaki","year":"2007","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1111\/hepr.12892","article-title":"Trehalose activates autophagy and decreases proteasome inhibitor-induced endoplasmic reticulum stress and oxidative stress-mediated cytotoxicity in hepatocytes","volume":"48","author":"Honma","year":"2018","journal-title":"Hepatol. Res."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1182\/bloodadvances.2018026880","article-title":"Targeting ubiquitin-activating enzyme induces ER stress-mediated apoptosis in B-cell lymphoma cells","volume":"3","author":"Best","year":"2019","journal-title":"Blood Adv."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"8567","DOI":"10.1073\/pnas.0503221102","article-title":"Small-molecule inhibition of proteasome and aggresome function induces synergistic antitumor activity in multiple myeloma","volume":"102","author":"Hideshima","year":"2005","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_71","first-page":"958","article-title":"Peroxisome proliferator-activated receptor gamma agonists induce proteasome-dependent degradation of cyclin D1 and estrogen receptor alpha in MCF-7 breast cancer cells","volume":"63","author":"Qin","year":"2003","journal-title":"Cancer Res."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1006\/bbrc.1996.1546","article-title":"Proteasome-dependent regulation of p21WAF1\/CIP1 expression","volume":"227","author":"Blagosklonny","year":"1996","journal-title":"Biochem. Biophys Res. Commun."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1126\/science.7624798","article-title":"Role of the ubiquitin-proteasome pathway in regulating abundance of the cyclin-dependent kinase inhibitor p27","volume":"269","author":"Pagano","year":"1995","journal-title":"Science"},{"key":"ref_74","doi-asserted-by":"crossref","unstructured":"Granato, M., Santarelli, R., Lotti, L.V., Di Renzo, L., Gonnella, R., Garufi, A., Trivedi, P., Frati, L., D\u2019Orazi, G., and Faggioni, A. (2013). JNK and macroautophagy activation by bortezomib has a pro-survival effect in primary effusion lymphoma cells. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0075965"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.canlet.2011.09.020","article-title":"Bortezomib induces autophagy in head and neck squamous cell carcinoma cells via JNK activation","volume":"314","author":"Li","year":"2012","journal-title":"Cancer Lett."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1039\/C4BM00365A","article-title":"Tumor extracellular acidity activated \u201coff-on\u201d release of bortezomib from a biocompatible dendrimer","volume":"3","author":"Wang","year":"2015","journal-title":"Biomater. Sci."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"419","DOI":"10.3322\/caac.21204","article-title":"Chemotherapy-induced peripheral neurotoxicity: A critical analysis","volume":"63","author":"Park","year":"2013","journal-title":"CA Cancer J. Clin."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.1345\/aph.1E620","article-title":"Stability of bortezomib 1-mg\/mL solution in plastic syringe and glass vial","volume":"39","author":"Cisternino","year":"2005","journal-title":"Ann. Pharmacother."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/S1535-6108(04)00120-5","article-title":"The development of proteasome inhibitors as anticancer drugs","volume":"5","author":"Adams","year":"2004","journal-title":"Cancer Cell"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1038\/nrd3321","article-title":"Ubiquitin-like protein conjugation and the ubiquitin-proteasome system as drug targets","volume":"10","author":"Bedford","year":"2011","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1021\/acs.chemrev.5b00300","article-title":"Synthesis and Applications of Boronic Acid-Containing Polymers: From Materials to Medicine","volume":"116","author":"Brooks","year":"2016","journal-title":"Chem. Rev."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"2864","DOI":"10.1002\/anie.201107144","article-title":"Well-defined, reversible boronate crosslinked nanocarriers for targeted drug delivery in response to acidic pH values and cis-diols","volume":"51","author":"Li","year":"2012","journal-title":"Angew. Chem. Int. Ed. Engl."},{"key":"ref_83","first-page":"4373","article-title":"Acid pH in tumors and its potential for therapeutic exploitation","volume":"49","author":"Tannock","year":"1989","journal-title":"Cancer Res."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1016\/j.thromres.2007.06.013","article-title":"Effects of bortezomib on platelet aggregation and ATP release in human platelets, in vitro","volume":"121","author":"Avcu","year":"2008","journal-title":"Thromb. Res."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"5101","DOI":"10.1158\/1078-0432.CCR-10-3367","article-title":"Treatment-induced oxidative stress and cellular antioxidant capacity determine response to bortezomib in mantle cell lymphoma","volume":"17","author":"Weniger","year":"2011","journal-title":"Clin. Cancer Res."},{"key":"ref_86","doi-asserted-by":"crossref","unstructured":"Tibullo, D., Giallongo, C., Romano, A., Vicario, N., Barbato, A., Puglisi, F., Parenti, R., Amorini, A.M., Wissam Saab, M., and Tavazzi, B. (2020). Mitochondrial Functions, Energy Metabolism and Protein Glycosylation are Interconnected Processes Mediating Resistance to Bortezomib in Multiple Myeloma Cells. Biomolecules, 10.","DOI":"10.3390\/biom10050696"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1111\/j.1365-2141.2011.08820.x","article-title":"VcR-CVAD induction chemotherapy followed by maintenance rituximab in mantle cell lymphoma: A Wisconsin Oncology Network study","volume":"155","author":"Chang","year":"2011","journal-title":"Br. J. Haematol."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1182\/blood-2013-08-523845","article-title":"Phase 2 study of VcR-CVAD with maintenance rituximab for untreated mantle cell lymphoma: An Eastern Cooperative Oncology Group study (E1405)","volume":"123","author":"Chang","year":"2014","journal-title":"Blood"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"3557","DOI":"10.1182\/blood-2006-08-036947","article-title":"Extended follow-up of a phase 3 trial in relapsed multiple myeloma: Final time-to-event results of the APEX trial","volume":"110","author":"Richardson","year":"2007","journal-title":"Blood"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1002\/ajh.21788","article-title":"Phase II trial of weekly bortezomib in combination with rituximab in untreated patients with Waldenstr\u00f6m Macroglobulinemia","volume":"85","author":"Ghobrial","year":"2010","journal-title":"Am. J. Hematol."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1200\/JCO.2010.31.1142","article-title":"Bortezomib plus CHOP-rituximab for previously untreated diffuse large B-cell lymphoma and mantle cell lymphoma","volume":"29","author":"Ruan","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"3223","DOI":"10.1016\/j.ejca.2012.06.003","article-title":"Bortezomib in combination with CHOP as first-line treatment for patients with stage III\/IV peripheral T-cell lymphomas: A multicentre, single-arm, phase 2 trial","volume":"48","author":"Kim","year":"2012","journal-title":"Eur. J. Cancer"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"465","DOI":"10.3816\/CBC.2010.n.061","article-title":"Phase II study of bortezomib and pegylated liposomal doxorubicin in the treatment of metastatic breast cancer","volume":"10","author":"Irvin","year":"2010","journal-title":"Clin. Breast Cancer"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"5025","DOI":"10.1200\/JCO.2006.06.1853","article-title":"Randomized phase II study of bortezomib alone and bortezomib in combination with docetaxel in previously treated advanced non-small-cell lung cancer","volume":"24","author":"Fanucchi","year":"2006","journal-title":"J. Clin. Oncol."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"2609","DOI":"10.1056\/NEJMoa030288","article-title":"A phase 2 study of bortezomib in relapsed, refractory myeloma","volume":"348","author":"Richardson","year":"2003","journal-title":"N. Engl. J. Med."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1007\/s40262-018-0679-9","article-title":"Clinical Pharmacokinetics and Pharmacodynamics of Bortezomib","volume":"58","author":"Tan","year":"2019","journal-title":"Clin. Pharmacokinet."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"4916","DOI":"10.1158\/0008-5472.CAN-16-1974","article-title":"Commentary on \u201cProteasome Inhibitors: A Novel Class of Potent and Effective Antitumor Agents\u201d","volume":"76","author":"Tew","year":"2016","journal-title":"Cancer Res."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1007\/s00280-010-1283-3","article-title":"Pharmacokinetic and pharmacodynamic study of two doses of bortezomib in patients with relapsed multiple myeloma","volume":"67","author":"Reece","year":"2011","journal-title":"Cancer Chemother. Pharmacol."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1007\/s40262-012-0010-0","article-title":"Pharmacokinetic, pharmacodynamic and covariate analysis of subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma","volume":"51","author":"Moreau","year":"2012","journal-title":"Clin. Pharmacokinet."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1124\/dmd.104.002956","article-title":"Human metabolism of the proteasome inhibitor bortezomib: Identification of circulating metabolites","volume":"33","author":"Pekol","year":"2005","journal-title":"Drug Metab. Dispos."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1007\/s00280-011-1637-5","article-title":"Dose-escalating and pharmacological study of bortezomib in adult cancer patients with impaired renal function: A National Cancer Institute Organ Dysfunction Working Group Study","volume":"68","author":"Leal","year":"2011","journal-title":"Cancer Chemother. Pharmacol."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"2954","DOI":"10.1158\/1078-0432.CCR-11-2873","article-title":"Pharmacokinetics and safety of bortezomib in patients with advanced malignancies and varying degrees of liver dysfunction: Phase I NCI Organ Dysfunction Working Group Study NCI-6432","volume":"18","author":"LoRusso","year":"2012","journal-title":"Clin. Cancer Res."},{"key":"ref_103","first-page":"119","article-title":"Analysis of bortezomib treatment efficacy and adverse reactions for patients with follicular lymphoma","volume":"23","author":"Li","year":"2015","journal-title":"Zhongguo Shi Yan Xue Ye Xue Za Zhi"},{"key":"ref_104","first-page":"2505","article-title":"A phase I trial of the novel proteasome inhibitor PS341 in advanced solid tumor malignancies","volume":"8","author":"Aghajanian","year":"2002","journal-title":"Clin. Cancer Res."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"4420","DOI":"10.1200\/JCO.2002.01.133","article-title":"Phase I trial of the proteasome inhibitor PS-341 in patients with refractory hematologic malignancies","volume":"20","author":"Orlowski","year":"2002","journal-title":"J. Clin. Oncol."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"S52","DOI":"10.1111\/jns.12338","article-title":"Bortezomib and other proteosome inhibitors-induced peripheral neurotoxicity: From pathogenesis to treatment","volume":"24","author":"Velasco","year":"2019","journal-title":"J. Peripher. Nerv. Syst."},{"key":"ref_107","doi-asserted-by":"crossref","unstructured":"Yamamoto, S., and Egashira, N. (2021). Pathological Mechanisms of Bortezomib-Induced Peripheral Neuropathy. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22020888"},{"key":"ref_108","first-page":"282","article-title":"Managing thrombocytopenia associated with cancer chemotherapy","volume":"29","author":"Kuter","year":"2015","journal-title":"Oncology"},{"key":"ref_109","first-page":"14","article-title":"Pharmacology, pharmacokinetics, and practical applications of bortezomib","volume":"18","author":"Schwartz","year":"2004","journal-title":"Oncology"},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1038\/leu.2011.256","article-title":"Impaired bortezomib binding to mutant \u03b25 subunit of the proteasome is the underlying basis for bortezomib resistance in leukemia cells","volume":"26","author":"Franke","year":"2012","journal-title":"Leukemia"},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"2489","DOI":"10.1182\/blood-2007-08-104950","article-title":"Molecular basis of bortezomib resistance: Proteasome subunit beta5 (PSMB5) gene mutation and overexpression of PSMB5 protein","volume":"112","author":"Oerlemans","year":"2008","journal-title":"Blood"},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1080\/10428190902895780","article-title":"Dysregulation of unfolded protein response partially underlies proapoptotic activity of bortezomib in multiple myeloma cells","volume":"50","author":"Dong","year":"2009","journal-title":"Leuk. Lymphoma"},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"1963","DOI":"10.1002\/ijc.32615","article-title":"The NEDD4-1 E3 ubiquitin ligase: A potential molecular target for bortezomib sensitivity in multiple myeloma","volume":"146","author":"Huang","year":"2020","journal-title":"Int. J. Cancer"},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"2399","DOI":"10.1080\/10428194.2020.1775204","article-title":"Novel tumor-targeted liposomes comprised of an MDM2 antagonist plus proteasome inhibitor display anti-tumor activity in a xenograft model of bortezomib-resistant Waldenstrom macroglobulinemia","volume":"61","author":"Madamsetty","year":"2020","journal-title":"Leuk. Lymphoma"},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"6037","DOI":"10.1038\/s41467-020-19932-1","article-title":"Tumor microenvironment-targeted nanoparticles loaded with bortezomib and ROCK inhibitor improve efficacy in multiple myeloma","volume":"11","author":"Federico","year":"2020","journal-title":"Nat. Commun."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"19355","DOI":"10.1021\/acsami.8b01954","article-title":"Dual pH-Responsive Shell-Cleavable Polycarbonate Micellar Nanoparticles for in Vivo Anticancer Drug Delivery","volume":"10","author":"Liu","year":"2018","journal-title":"ACS Appl. Mater. Interfaces"},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"119885","DOI":"10.1016\/j.ijpharm.2020.119885","article-title":"Dopamine-modified poly(\u03b5-caprolactone) micelles for pH controlled delivery of bortezomib","volume":"590","author":"Liu","year":"2020","journal-title":"Int. J. Pharm."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1016\/j.actbio.2018.09.022","article-title":"Hyaluronic acid shell and disulfide-crosslinked core micelles for in vivo targeted delivery of bortezomib for the treatment of multiple myeloma","volume":"80","author":"Gu","year":"2018","journal-title":"Acta Biomater."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"19722","DOI":"10.1039\/C5NR04828A","article-title":"Smart micelle@polydopamine core-shell nanoparticles for highly effective chemo-photothermal combination therapy","volume":"7","author":"Zhang","year":"2015","journal-title":"Nanoscale"},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"41003","DOI":"10.1021\/acsami.8b07527","article-title":"A Targeted and pH-Responsive Bortezomib Nanomedicine in the Treatment of Metastatic Bone Tumors","volume":"10","author":"Wang","year":"2018","journal-title":"ACS Appl. Mater. Interfaces"},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"e78","DOI":"10.1016\/j.jconrel.2015.05.130","article-title":"Catechol-grafted dendrimer with a neutral shell allows pH-triggered \"off-on\" release of bortezomib","volume":"213","author":"Wang","year":"2015","journal-title":"J. Control Release"},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.ijbiomac.2021.04.161","article-title":"Encapsulation and pH-responsive release of bortezomib by dopamine grafted hyaluronate nanogels","volume":"183","author":"Liu","year":"2021","journal-title":"Int. J. Biol. Macromol."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"33594","DOI":"10.1038\/srep33594","article-title":"pH\/NIR Light-Controlled Multidrug Release via a Mussel-Inspired Nanocomposite Hydrogel for Chemo-Photothermal Cancer Therapy","volume":"6","author":"GhavamiNejad","year":"2016","journal-title":"Sci. Rep."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"6191","DOI":"10.1021\/acs.nanolett.0c02515","article-title":"Spatiotemporally Targeted Nanomedicine Overcomes Hypoxia-Induced Drug Resistance of Tumor Cells after Disrupting Neovasculature","volume":"20","author":"Chen","year":"2020","journal-title":"Nano Lett."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"13274","DOI":"10.1021\/acsami.7b14319","article-title":"Injectable Coacervate Hydrogel for Delivery of Anticancer Drug-Loaded Nanoparticles in vivo","volume":"10","author":"Lee","year":"2018","journal-title":"ACS Appl. Mater. Interfaces"},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"2377","DOI":"10.1021\/nn5070343","article-title":"Protease-mediated release of chemotherapeutics from mesoporous silica nanoparticles to ex vivo human and mouse lung tumors","volume":"9","author":"Argyo","year":"2015","journal-title":"ACS Nano"},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1016\/j.biopha.2014.04.003","article-title":"Chitosan magnetic nanoparticles for pH responsive Bortezomib release in cancer therapy","volume":"68","author":"Unsoy","year":"2014","journal-title":"Biomed. Pharmacother."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"110674","DOI":"10.1016\/j.colsurfb.2019.110674","article-title":"Histone H2A-peptide-hybrided upconversion mesoporous silica nanoparticles for bortezomib\/p53 delivery and apoptosis induction","volume":"186","author":"Rong","year":"2020","journal-title":"Colloids Surf. B Biointerfaces"},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"18119","DOI":"10.1039\/C5NR05844A","article-title":"A smart magnetic nanoplatform for synergistic anticancer therapy: Manoeuvring mussel-inspired functional magnetic nanoparticles for pH responsive anticancer drug delivery and hyperthermia","volume":"7","author":"Sasikala","year":"2015","journal-title":"Nanoscale"},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"10688","DOI":"10.1021\/acsnano.0c05332","article-title":"Bortezomib-Encapsulated CuS\/Carbon Dot Nanocomposites for Enhanced Photothermal Therapy via Stabilization of Polyubiquitinated Substrates in the Proteasomal Degradation Pathway","volume":"14","author":"Yu","year":"2020","journal-title":"ACS Nano"},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1002\/mabi.201300401","article-title":"Development of P22 viral capsid nanocomposites as anti-cancer drug, bortezomib (BTZ), delivery nanoplatforms","volume":"14","author":"Min","year":"2014","journal-title":"Macromol. Biosci."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1248\/bpb.b16-00624","article-title":"Liposomal Delivery Systems: Design Optimization and Current Applications","volume":"40","author":"Ishida","year":"2017","journal-title":"Biol. Pharm. Bull."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.jconrel.2019.04.025","article-title":"Liposomes used as a vaccine adjuvant-delivery system: From basics to clinical immunization","volume":"303","author":"Wang","year":"2019","journal-title":"J. Control Release"},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"2373","DOI":"10.1007\/s11095-016-1958-5","article-title":"Nanoparticle-Based Medicines: A Review of FDA-Approved Materials and Clinical Trials to Date","volume":"33","author":"Bobo","year":"2016","journal-title":"Pharm. Res."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1517\/17425247.2013.783009","article-title":"Reduction-sensitive degradable micellar nanoparticles as smart and intuitive delivery systems for cancer chemotherapy","volume":"10","author":"Sun","year":"2013","journal-title":"Expert Opin. Drug Deliv."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1007\/s12272-018-1008-4","article-title":"Recent progress in dendrimer-based nanomedicine development","volume":"41","author":"Kim","year":"2018","journal-title":"Arch. Pharm. Res."},{"key":"ref_137","doi-asserted-by":"crossref","unstructured":"Chauhan, A.S. (2018). Dendrimers for Drug Delivery. Molecules, 23.","DOI":"10.3390\/molecules23040938"},{"key":"ref_138","doi-asserted-by":"crossref","unstructured":"Petrova, V.A., Elokhovskiy, V.Y., Raik, S.V., Poshina, D.N., Romanov, D.P., and Skorik, Y.A. (2019). Alginate Gel Reinforcement with Chitin Nanowhiskers Modulates Rheological Properties and Drug Release Profile. Biomolecules, 9.","DOI":"10.3390\/biom9070291"},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1208\/s12249-016-0579-y","article-title":"Growth Factor-Loaded Nano-niosomal Gel Formulation and Characterization","volume":"18","author":"Moghassemi","year":"2017","journal-title":"AAPS PharmSciTech"},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"2053","DOI":"10.1039\/C8CS00618K","article-title":"Photothermal therapy and photoacoustic imaging via nanotheranostics in fighting cancer","volume":"48","author":"Liu","year":"2019","journal-title":"Chem. Soc. Rev."},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1208\/s12248-015-9780-2","article-title":"A Review of Clinical Translation of Inorganic Nanoparticles","volume":"17","author":"Anselmo","year":"2015","journal-title":"AAPS J."},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/s41573-020-0090-8","article-title":"Engineering precision nanoparticles for drug delivery","volume":"20","author":"Mitchell","year":"2021","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1039\/C9NH00291J","article-title":"Biomimetic nanoparticle technology for cardiovascular disease detection and treatment","volume":"5","author":"Park","year":"2020","journal-title":"Nanoscale Horiz."},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"120142","DOI":"10.1016\/j.biomaterials.2020.120142","article-title":"Programming cell pyroptosis with biomimetic nanoparticles for solid tumor immunotherapy","volume":"254","author":"Zhao","year":"2020","journal-title":"Biomaterials"},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"10049","DOI":"10.1021\/acsnano.6b04695","article-title":"Cancer Cell Membrane-Biomimetic Nanoparticles for Homologous-Targeting Dual-Modal Imaging and Photothermal Therapy","volume":"10","author":"Chen","year":"2016","journal-title":"ACS Nano"}],"container-title":["Biomolecules"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2218-273X\/12\/1\/51\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T07:56:00Z","timestamp":1760169360000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2218-273X\/12\/1\/51"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12,30]]},"references-count":145,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,1]]}},"alternative-id":["biom12010051"],"URL":"https:\/\/doi.org\/10.3390\/biom12010051","relation":{},"ISSN":["2218-273X"],"issn-type":[{"value":"2218-273X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,12,30]]}}}